Marc Frahm

Genocea Biosciences Inc GNCA) announced late Monday that it is effecting a strategic shift to immuno-oncology. The company also said it would focus on the development of neoantigen cancer vaccines, including GEN-009, and that it would explore strategic alternatives for GEN-003. Reacting to the...